For research use only. Not for therapeutic Use.
Solithromycin（Cat No.:I004815）is a next-generation macrolide antibiotic developed to treat bacterial infections, particularly community-acquired bacterial pneumonia (CABP). As a fluoroketolide, it binds to bacterial ribosomes more effectively than traditional macrolides, providing robust activity against resistant strains of Streptococcus pneumoniae and Haemophilus influenzae. Solithromycin can be administered orally or intravenously, offering flexibility in treatment. Its enhanced binding profile and resistance to macrolide resistance mechanisms make it a promising option in respiratory infections, potentially reducing the need for stronger antibiotics and supporting effective bacterial management in clinical settings.
| Catalog Number | I004815 |
| CAS Number | 760981-83-7 |
| Synonyms | (3aS,4R,7S,9S,10R,11S,13R,15R,15aR)-1-(4-(4-(3-aminophenyl)-1H-1,2,3-triazol-1-yl)butyl)-10-(((2R,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-7-fluoro-11-methoxy-3a,7,9,11,13,15-hexamethyloctahydro-1H-[1]oxacyc |
| Molecular Formula | C43H65FN6O10 |
| Purity | ≥95% |
| Target | Antibiotic |
| Solubility | DMSO: ≥ 32 mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | (1S,2R,5S,7R,8R,9R,11R,13R,14R)-15-[4-[4-(3-aminophenyl)triazol-1-yl]butyl]-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-5-fluoro-9-methoxy-1,5,7,9,11,13-hexamethyl-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone |
| InChI | InChI=1S/C43H65FN6O10/c1-12-32-43(8)35(50(40(55)60-43)19-14-13-18-49-23-30(46-47-49)28-16-15-17-29(45)21-28)26(4)33(51)24(2)22-41(6,56-11)37(27(5)36(53)42(7,44)39(54)58-32)59-38-34(52)31(48(9)10)20-25(3)57-38/h15-17,21,23-27,31-32,34-35,37-38,52H,12-14,18 |
| InChIKey | IXXFZUPTQVDPPK-ZAWHAJPISA-N |
| SMILES | O=C(N1CCCCN2N=NC(C3=CC=CC(N)=C3)=C2)O[C@]([C@@]1([H])[C@H]4C)(C)[C@@H](CC)OC([C@@](C)(F)C([C@H](C)[C@@H](O[C@@]5([H])[C@H](O)[C@@H](N(C)C)C[C@@H](C)O5)[C@](C)(OC)C[C@@H](C)C4=O)=O)=O |
| Reference | </br>1:Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea. Mancuso AM, Gandhi MA, Slish J.J Pharm Pract. 2017 Jan 1:897190017708073. doi: 10.1177/0897190017708073. [Epub ahead of print] PMID: 28490220 </br>2:Surveillance of the activity of solithromycin (CEM-101) against bacteria from respiratory tract infections. Hawser S, Morrissey I, Lemos B, Keedy K, Fernandes P.Int J Antimicrob Agents. 2017 May 5. pii: S0924-8579(17)30142-5. doi: 10.1016/j.ijantimicag.2017.01.035. [Epub ahead of print] PMID: 28483717 </br>3:Solithromycin: A novel ketolide antibiotic. Buege MJ, Brown JE, Aitken SL.Am J Health Syst Pharm. 2017 Apr 21. pii: ajhp160934. doi: 10.2146/ajhp160934. [Epub ahead of print] PMID: 28432048 </br>4:Solithromycin rejection chills antibiotic sector. Owens B.Nat Biotechnol. 2017 Mar 7;35(3):187-188. doi: 10.1038/nbt0317-187. No abstract available. PMID: 28267725 </br>5:Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty AJ, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.Drugs. 2016 Dec;76(18):1737-1757. Review. PMID: 27909995 </br>6:In-vitro activity of solithromycin against anaerobic bacteria from the normal intestinal microbiota. Weintraub A, Rashid MU, Nord CE.Anaerobe. 2016 Dec;42:119-122. doi: 10.1016/j.anaerobe.2016.10.002. Epub 2016 Oct 7. PMID: 27725229 </br>7:Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjects. Darpo B, Sager PT, Fernandes P, Jamieson BD, Keedy K, Zhou M, Oldach D.J Antimicrob Chemother. 2017 Feb;72(2):515-521. doi: 10.1093/jac/dkw428. Epub 2016 Oct 26. PMID: 27798210 </br>8:Solithromycin for the treatment of community-acquired bacterial pneumonia. Viasus D, Ramos O, Ramos L, Simonetti AF, Carratalà J.Expert Rev Respir Med. 2017 Jan;11(1):5-12. doi: 10.1080/17476348.2017.1249852. Epub 2016 Oct 31. PMID: 27753516 </br>9:In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen. Hardy DJ, Vicino D, Fernandes P.Antimicrob Agents Chemother. 2016 Nov 21;60(12):7043-7045. Print 2016 Dec. PMID: 27620481 Free PMC Article</br>10:The solithromycin journey-It is all in the chemistry. Fernandes P, Martens E, Bertrand D, Pereira D.Bioorg Med Chem. 2016 Dec 15;24(24):6420-6428. doi: 10.1016/j.bmc.2016.08.035. Epub 2016 Aug 22. PMID: 27595539 Free Article |
